PharmaCorp Announces Grant of Stock Options

Summary of PharmaCorp Rx Inc. News Core Viewpoint PharmaCorp Rx Inc. has granted stock options to its directors, officers, employees, and consultants, with specific terms and conditions, while relying on exemptions from formal valuation and minority approval requirements under applicable regulations. Group 1: Stock Options Grant - PharmaCorp has granted a total of 827,603 options to purchase common shares at an exercise price of $0.48, expiring on July 1, 2035, pending approval from the TSX Venture Exchange [1] - The company utilized section 5.5(b) of Multilateral Instrument 61-101 to exempt the formal valuation requirements, as its common shares are only listed on the TSXV [2] - The exemption from minority approval requirements was based on section 5.7(a) of MI 61-101, as the fair market value of the options granted did not exceed 25% of the Corporation's market capitalization [2] Group 2: Company Operations - PharmaCorp operates three PharmaChoice bannered pharmacies in Canada and plans to acquire more as they become available, in line with its strategic alliance with PharmaChoice Canada [3] - The company also intends to acquire independently owned pharmacies not affiliated with PharmaChoice Canada and will operate them under the PharmaChoice Canada banner [3] - PharmaCorp shares are traded on the TSX Venture Exchange under the symbol PCRX [3]